Schreiber, Hans

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 4,148

Inflammation as a Tumor Promoter in Cancer Induction

Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology

NF-κB Signaling PathwaysImmune cells in cancer

Cited by 640

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

Posey, A. D., Schwab, R. D., Boesteanu, A. C., Steentoft, C., Mandel, U., Engels, B., Stone, J. D., Madsen, T. D., Schreiber, K., Haines, K. M., et al. (2016) · Immunity

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 594

Tumor-associated fibroblasts predominantly come from local and not circulating precursors

Arina, A., Idel, C., Hyjek, E. M., Alegre, M.-L., Wang, Y., Bindokas, V. P., Weichselbaum, R. R., & Schreiber, H. (2016) · Proceedings of the National Academy of Sciences

Cancer Cells and MetastasisTGF-β signaling in diseases

Cited by 238

Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells

Friedman, J., Moore, E. C., Zolkind, P., Robbins, Y., Clavijo, P. E., Sun, L., Greene, S., Morisada, M. V., Mydlarz, W. K., Schmitt, N., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 88